Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation

NCT00150228 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00150228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00150228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2001
Completion date
September 30, 2002
Enrollment
300
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation